Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-Henipavirus monoclonal antibody with broad-spectrum neutralizing activity and application

A monoclonal antibody and virus technology, applied in the fields of immunology and microbiology, to achieve good binding activity and excellent broad-spectrum effect

Active Publication Date: 2022-01-25
ACADEMY OF MILITARY MEDICAL SCI
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no vaccine available for human beings, and only one monoclonal antibody m102.4 has entered clinical trials for antibody drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-Henipavirus monoclonal antibody with broad-spectrum neutralizing activity and application
  • Anti-Henipavirus monoclonal antibody with broad-spectrum neutralizing activity and application
  • Anti-Henipavirus monoclonal antibody with broad-spectrum neutralizing activity and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Example 1 Screening and Preparation of Antibodies

[0045] 1. Blood Sample Collection

[0046] Female rhesus macaques were immunized three times, that is, on days 0, 28, and 49, intramuscular injection was used to immunize the adenovirus vector Nipah virus candidate vaccine, recombinant NiV G protein, and recombinant HeV G protein, respectively. Finally, blood samples from rhesus monkeys were collected on day 77.

[0047] 2. FITC-labeled NiV-BD G protein

[0048] To sort antigen-specific memory B cells, FITC-labeled antigen protein NiV-BD G was used. Methods as below:

[0049] 1) Fluorescein Isothiocyanate FITC (SIGMA, F4274) was dissolved in DMSO at a concentration of 20 mg / mL. Take 100μL NiV-BD G protein (3.3mg / mL), add buffer (pH 9.6 carbonate buffer) to 400μL.

[0050] 2) Add 8 μL FITC to the NiV-BD G protein solution, and incubate at 4° C. in the dark for 3 hours.

[0051] 3) Use a 30kDa ultrafiltration tube to replace the solution with PBS until the filtrate...

Embodiment 2

[0114] Example 2.ELISA detection of antibody binding activity

[0115] 1) One day before the experiment, the 96-well ELISA plate was coated with 1 μg / mL NiV-BD / MY or HeV G protein (NiV-BD G Genbank accession number: AY988601.1, NiV-MY G Genbank accession number: FN869553.1, HeV G Genbank accession number: NC_001906.3), 100 μL of coating per well, overnight at 4°C.

[0116] 2) On the day of the experiment, wash 5 times with a plate washer, add 100 μL of blocking solution to each well, and place at room temperature for 1 hour.

[0117] 3) Wash the plate, add 150 μL of monoclonal antibody with a concentration of 20 μg / mL to the first well, and add 100 μL of diluent to the remaining wells. Aspirate 50 μL from the first well and add to the second well, and so on, dilute the solution in a 1:3 gradient to a final volume of 100 μL in each well. Let stand at room temperature for 1 hour.

[0118] 4) Wash the plate, dilute HPR-labeled goat anti-human IgG secondary antibody at 1:10000 ...

Embodiment 31E5

[0127] Example 3.1E5 Affinity Determination

[0128] 1) Dilute 1E5 to concentrations of 100nM, 50nM, 25nM, 12.5nM, 6.25nM, 3.13nM, 1.56nM.

[0129] 2) Prepare the Octet RED instrument (fortéBIO, Pall Corp, USA), and set the kinetic detection method in the supporting software DataAnalysis Software v9.0. The method includes 5 steps: Baseline, Loading, Baseline, Association and Dissociation, and the duration of each step is set to 100s, 180s, 60s, 300s and 600s respectively.

[0130] 3) Place the antibody, antigen and PBS buffer solution to start detection. After the experiment, the software DataAnalysis was used for data processing, and the equilibrium dissociation constant KD value and the binding-dissociation curve of 1E5 and Henipa virus G protein were calculated and fitted. like Figure 5 Shown, wherein, A, B, C are the G protein binding dissociation curves of 1E5 and HeV, NiV-BD and NiV-MY, respectively. The calculation results of KD value are shown in the table below. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Affinity constantaaaaaaaaaa
Login to View More

Abstract

The invention discloses an anti-Henipavirus monoclonal antibody with broad-spectrum neutralizing activity. The antibody is composed of a monkey-derived variable region and a human-derived constant region, wherein light and heavy chains of the monkey-derived variable region have unique CDR regions. The antibody provided by the invention shows excellent broad spectrum on antigen binding capacity, and has good binding activity with both a Nipah virus glycoprotein G and a Henipavirus glycoprotein G. The antibody can effectively neutralize Nipah and Hendra pseudoviruses; and the neutralizing activity of the antibody is enhanced along with the increase of the concentration of the antibody, and near 100% neutralization can be realized on the Nipah and Hendra pseudoviruses at the concentration of 1 microgram / mL. The invention further discloses an application of the anti-Henipavirus glycoprotein G monoclonal antibody in preparation of Henipavirus disease treatment drugs.

Description

technical field [0001] The invention discloses a monoclonal antibody, belonging to the fields of immunology and microbiology. Background technique [0002] Nipah virus (NiV) and Hendra virus (HeV) both belong to the Henipavirus genus of the Paramyxoviridae family and are single-stranded negative-sense RNA viruses. NiV and HeV are zoonotic viruses that can infect humans through contact and cause fatal respiratory and neurological diseases. The natural hosts of NiV and HeV are fruit bats, but their transmission routes are slightly different. HeV has only found the transmission route of fruit bat-horse-human, while NiV can be transmitted through fruit bat-pig-human. Directly through bat-to-human and human-to-human transmission. [0003] HeV first appeared in the town of Hendra, a suburb of Brisbane, Australia. The outbreak began in 1994. A total of 21 horses and two people were sick. Horses were identified as intermediate hosts. People who cared for or autopsied sick or dead ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/10C12N15/13A61K39/42A61P31/14
CPCC07K16/1027A61P31/14C07K2317/565C07K2317/52C07K2317/76C07K2317/92C07K2317/24C07K16/10
Inventor 陈薇于长明刘渝娇范鹏飞张冠英李耀辉李建民迟象阳郝勐房婷董韵竹宋小红陈旖刘树玲
Owner ACADEMY OF MILITARY MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com